Compare Hyatt Hotels Corporation (H) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Hyatt Hotels Corporation trades at $159.3 (market cap $14.81B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.2× Hyatt Hotels Corporation's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.51%). Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| H | REGN | |
|---|---|---|
Market Cap | $14.81B | $76.40B |
Volume | 588,239 | 626,381 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $852.03 |
52-Week Low | $135.42 | $557.73 |
Typical Hold Time | 148 Days | 107 Days |
Enterprise Value | $18.71B | $71.12B |
Dividend Yield | 0.38% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $159.43, up 0.19% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock has beaten earnings estimates for the last three quarters, though Q3 2026 results are pending. Revenue grew to $7.10 billion in 2025, but net income was negative $52 million, reflecting margin pressure. Recent news highlights brand expansion and a strategic loyalty collaboration with Delta Air Lines, signaling growth initiatives amid mixed financial performance.
The outlook for Hyatt is cautiously optimistic, supported by analyst consensus and strategic partnerships, but high valuation multiples and inconsistent profitability pose risks. Upside potential exists if operational improvements and fee growth materialize, yet investors face headwinds from debt levels and competitive pressures in the hospitality sector.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
